170 related articles for article (PubMed ID: 15599805)
1. Decitabine. MGI Pharma Inc/SuperGen Inc.
Arthur C
IDrugs; 2004 Dec; 7(12):1113-32. PubMed ID: 15599805
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
Fenaux P
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S36-44. PubMed ID: 16341239
[TBL] [Abstract][Full Text] [Related]
3. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
4. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
Lyons J; Bayar E; Fine G; McCullar M; Rolens R; Rubinfeld J; Rosenfeld C
Curr Opin Investig Drugs; 2003 Dec; 4(12):1442-50. PubMed ID: 14763130
[TBL] [Abstract][Full Text] [Related]
5. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
Drugs R D; 2003; 4(3):179-84. PubMed ID: 12757405
[TBL] [Abstract][Full Text] [Related]
6. Decitabine.
Daskalakis M; Blagitko-Dorfs N; Hackanson B
Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
[TBL] [Abstract][Full Text] [Related]
7. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
Kuykendall JR
Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
[TBL] [Abstract][Full Text] [Related]
8. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
Issa JP
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S24-9. PubMed ID: 16341237
[TBL] [Abstract][Full Text] [Related]
9. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
Silverman LR; Mufti GJ
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
[TBL] [Abstract][Full Text] [Related]
10. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C; Lyko F
Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
[TBL] [Abstract][Full Text] [Related]
11. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
12. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
Drugs R D; 2003; 4(6):352-8. PubMed ID: 14584964
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA methylation.
Issa JP; Kantarjian HM
Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
[TBL] [Abstract][Full Text] [Related]
14. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors.
Nie J; Liu L; Li X; Han W
Cancer Lett; 2014 Nov; 354(1):12-20. PubMed ID: 25130173
[TBL] [Abstract][Full Text] [Related]
15. Decitabine in myelodysplastic syndromes: viewpoints.
Garcia-Manero G; Saba HI
Drugs; 2006; 66(7):959-60. PubMed ID: 16740015
[No Abstract] [Full Text] [Related]
16. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.
Samlowski WE; Leachman SA; Wade M; Cassidy P; Porter-Gill P; Busby L; Wheeler R; Boucher K; Fitzpatrick F; Jones DA; Karpf AR
J Clin Oncol; 2005 Jun; 23(17):3897-905. PubMed ID: 15753459
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic drugs: a longstanding story.
de Vos D
Semin Oncol; 2005 Oct; 32(5):437-42. PubMed ID: 16210083
[TBL] [Abstract][Full Text] [Related]
18. Decitabine is an effective treatment of idiopathic myelofibrosis.
Danilov AV; Relias V; Feeney DM; Miller KB
Br J Haematol; 2009 Apr; 145(1):131-2. PubMed ID: 19133981
[No Abstract] [Full Text] [Related]
19. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Lübbert M
Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
[No Abstract] [Full Text] [Related]
20. Decitabine and its role in the treatment of hematopoietic malignancies.
Plimack ER; Kantarjian HM; Issa JP
Leuk Lymphoma; 2007 Aug; 48(8):1472-81. PubMed ID: 17701577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
